Key Highlights
- Artelo Biosciences (ARTL) climbed more than 40% during pre-market hours on March 18, 2026
- The rally followed news of a fully-funded glaucoma research agreement with Belfast Health and Social Care Trust
- ART27.13, the company’s peripherally selective synthetic cannabinoid, will be evaluated in patients with glaucoma or ocular hypertension
- Glaucoma UK and the HSC R&D Division are providing complete funding, with initial patient enrollment anticipated in Q2 2026
- This development arrives weeks after a 1-for-3 reverse stock split became effective on March 10, 2026
Shares of Artelo Biosciences (ARTL) advanced more than 40% during Wednesday’s pre-market session following the company’s disclosure of a fully-funded clinical trial examining its synthetic cannabinoid compound ART27.13 for glaucoma treatment.
Artelo Biosciences, Inc., ARTL
The investigator-led research initiative emerged from a partnership agreement with the Belfast Health and Social Care Trust (BHSCT). Complete financial backing comes from Glaucoma UK alongside the HSC R&D Division.
Researchers will conduct a pilot, randomized, cross-over trial examining ART27.13’s potential to reduce intraocular pressure (IOP) among individuals diagnosed with glaucoma or ocular hypertension.
ART27.13 functions as a peripherally selective synthetic cannabinoid receptor agonist. This pharmaceutical design allows it to engage cannabinoid receptors located in peripheral tissues — particularly within ocular structures — while leaving the central nervous system unaffected.
Current glaucoma therapies rely heavily on topical eye drop formulations, which frequently encounter challenges with patient compliance and sustained efficacy over extended periods. According to Artelo, ART27.13’s molecular architecture may circumvent the psychotropic complications that have historically constrained cannabinoid-derived ophthalmic interventions.
Regulatory authorities have already granted approval for the study protocol, receiving clearance from an ethics review board and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Initial patient recruitment is scheduled to begin during Q2 2026.
Professor Augusto Azuara-Blanco will serve as principal investigator for the trial. He holds a position as clinical professor of ophthalmology at Queen’s University Belfast and maintains recognition as a distinguished authority in glaucoma research.
Glaucoma impacts over 80 million individuals globally, ranking among the primary causes of permanent vision loss. Increased IOP remains the principal modifiable risk element driving disease advancement.
Capital-Efficient Development Approach
CEO Greg Gorgas positioned the arrangement within the company’s broader resource-conscious development framework. The strategy allows external funding sources to manage this particular study while Artelo maintains concentrated efforts on ART27.13’s principal therapeutic target — cancer-related anorexia.
“This collaboration exemplifies our capital-efficient development strategy,” Gorgas said in the announcement. “Each study contributes to a growing body of evidence that could enhance the value of ART27.13.”
Terms of the partnership require Artelo to provide ART27.13 capsules serving as the Investigational Medicinal Product throughout the trial. All remaining financial obligations fall to the study’s external funding partners.
Financial Background
The pre-market rally emerged amid difficult financial circumstances. Artelo disclosed a net loss totaling $12.9 million for the fiscal year concluded December 31, 2025, representing an increase from the $9.8 million deficit recorded during the preceding year.
Cash reserves and investments measured just $0.6 million at that reporting date. InvestingPro’s Financial Health Score assigns the company a “WEAK” rating.
The company executed a 1-for-3 reverse stock split on March 10, 2026. Outstanding common shares contracted from approximately 2.1 million to 708,323 shares following the consolidation.
Before Wednesday’s movement, ARTL had dropped 67% throughout the preceding six-month period. The stock changed hands at $4.85 with a market capitalization around $3.47 million ahead of the pre-market advance.
The glaucoma research initiative marks Artelo’s inaugural venture into ophthalmology and establishes the company’s first externally-financed clinical collaboration.
